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Background 
Pancreatic cancer is the 4th most aggressive cancer in the western world with less than 34% of 
patients surviving past 5 years. Lack of specific symptoms results in delayed diagnosis. Theranostics 
are new platforms, which offer simultaneous diagnosis and therapy resulting in a decrease in 
treatment time. Here treatments are conjugated onto diagnostics by stimuli responsive binding 
allowing for controlled drug release resulting in a rapid and localised clinical effect. Hybrid 
nanoparticles are composed of an iron oxide core surrounded by a rigid gold shell. These particles 
undergo manipulation due to inherent magnetism of the core whilst laser irradiation of their gold 
shell results in localised heating due to surface plasmon resonance. Hence, they can be utlilised as 
diagnostics using MRI and laser irradiation can be used as a trigger for drug release. 
 
Methods  
Proof of concept studies have been carried out using a novel bisnaphthalamido (BNIP) based drug 
series. BNIPs are a series of novel compounds, which have exhibited exciting potential as 
chemotherapy agents. HNPs were fabricated and characterised using PCS, TEM, MRI, SQUID and zeta 
potential measurement. Drug conjugation and release was quantified using reverse phase HPLC. 
Cellular response and cytotoxicity assays were carried out using trypan blue exclusion, MTT assay 
and atomic force microscopy.  
 
Results and Discussion 
In our studies, we designed hybrid nanoparticles (50 nm) capable of drug loading onto their surface 
(3:1:0.25, Drug:Fe:Au). By exploiting the gold surface-to-drug interaction of a range of novel 
Bisnaphtalamido based agents a system with heat triggered drug release was produced. In vitro 
studies of these formulations showed the novel formulations possess a 10-fold lower IC50 value 
when compared with the free drug after only 24 h. These cytotoxicity studies combined with cellular 
uptake studies showed the formulations to be significantly more effective compared with 
gemcitabine. In vivo trials have commenced to further elucidate their viability for use as 
theranostics. 
 
Conclusion 
These data highlight the potential of HNPs as dual imaging agents and contrast agents for pancreatic 
cancer therapy. 
 
